Figure 2 |. Cross-priming capacity of DC is enhanced in Ythdf1^−/− mice.

a-c, WT or Ythdf1^−/− mice were injected s.c. with 10⁶ B16-OVA cells. The frequency of tumor-infiltrating OVA-Specific CD8⁺ T cells was assessed 12 days post tumor inoculation (a-b). Six days post tumor inoculation, lymphocytes from DLN were isolated and stimulated with 10 μg/ml OTI peptide. IFN-γ–producing cells were enumerated by ELISPOT assay (c). d, WT or Ythdf1^−/− mice were injected s.c. with 10⁶ MC38 cells. Six days post tumor inoculation, lymphocytes from DLN were isolated and stimulated with irradiated MC38 cells for 48 hours. e, Flt3L-DCs were co-cultured with necrotic B16-OVA overnight, and B220⁻ CD11c⁺ cells were purified and co-cultured with OT-I T cells. IFN-γ production was assessed by IFN-γ cytometric bead array. Data are representative of six biological replicates. f, 6 days after tumor inoculation, CD8⁺ or CD11b⁺ DCs were sorted from draining LNs. DCs were co-cultured with isolated OT-I cells for 3 days and analyzed by IFN-γ CBA. g-h, Formation of H-2K^b-SIINFEKL on tumor-infiltrating DCs from B16-OVA tumor-bearing WT and Ythdf1^−/− mice (g). Mean fluoresce intensity (MFI) is shown (h). i, WT mice were transferred with WT or Ythdf1^−/− bone marrow cells (BMCs) mixed with Zbtb46-DTR BMCs in 1:1 ratio. Six weeks after bone marrow chimera reconstitution, mice were injected s.c. with 1×10⁶ B16-OVA cells. 400 ng DT was administrated on the same day (+ DT). Tumor size was monitored over time. n, numbers of mice. Data are mean ± s.e.m. and were analyzed by two-tailed unpaired Student’s t-test. Data are representative of two independent experiments (a, g).